CRNX

NEUTRALM&A

Crinetics Pharmaceuticals, Inc.

2026-08-19

Price

$84.69

-0.04%

This is the 2026-08-19 snapshot — the signals and analysis for CRNX as of this single trading day.

View full CRNX research hub →

Score8.2Priority

Signals7/8 DNA3/13 Act · 1/4 Risk

SentimentNEUTRALScore: 7

Volume0.9xvs 20d avg

Analysis

Crinetics Pharmaceuticals (CRNX) is exhibiting classic merger arbitrage price action, trading tightly below Vertex Pharmaceuticals' $85.00 all-cash acquisition offer. Despite recent noise from shareholder lawsuits and supplemental proxy filings, the stock remains anchored at $84.69. This stability is supported by SURGE and QUIET_STORM signals, reflecting institutional absorption and high conviction in the deal's closure. Furthermore, the broader RISK_ON macro regime insulates the transaction from systemic financing shocks, keeping the arbitrage spread exceptionally tight ahead of the August 28th shareholder vote.

Fired Signals

SURGEALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSMARKET LEADERPERFECT STACKSELLER FATIGUEPANIC REVERSALBARGAIN HUNTEREXTENSION

Key Takeaways

Actionable Thesis: CRNX is a high-conviction merger arbitrage play pinned near the $85 acquisition price, offering a tight spread that indicates near-certainty of deal completion [1.2.7].
Key Risk: Tail-risk of deal collapse or delay due to unforeseen regulatory hurdles or escalation in the recently disclosed shareholder litigation.
What to Watch: The August 28 special shareholder meeting is the definitive catalyst; maintain a strict stop below the $83.52 line-in-the-sand to protect against deal failure.

← Back to 2026-08-19 View Full CRNX History →Yahoo Finance &nearr;